Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021158666 - SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME

Publication Number WO/2021/158666
Publication Date 12.08.2021
International Application No. PCT/US2021/016418
International Filing Date 03.02.2021
IPC
C07D 403/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07C 55/22 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
55Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
22Tricarboxylic acids
A61K 31/404 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61P 13/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
CPC
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
C07B 2200/13
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
13Crystalline forms, e.g. polymorphs
C07C 47/58
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
47Compounds having —CHO groups
52Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
575containing ether groups, groups, groups, or groups
58Vanillin
C07C 55/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
55Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
02Dicarboxylic acids
12Glutaric acid
C07D 403/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants
  • VERTEX PHARMACEUTICALS INCORPORATED [US]/[US]
Inventors
  • GAGNON, Kevin James
  • IYEMPERUMAL, Satish Kumar
  • JUDELSON, Michael David
  • LAI, Mei-Hsiu
  • LI, Jicong
  • MAGUIRE, Courtney K.
  • MEDEK, Ales
  • MINCHOM, Jack Raphael
  • PERESYPKIN, Andrey
  • SARPAL, Kanika
  • SHI, Yi
  • SHRESTHA, Muna
  • WITKOS, Faith
Agents
  • MCDONELL, Leslie A.
Priority Data
62/970,00204.02.2020US
63/038,26712.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME
(FR) FORMES À L'ÉTAT SOLIDE DE L'INHIBITEUR D'APOL1 ET PROCÉDÉS D'UTILISATION ASSOCIÉS
Abstract
(EN) The disclosure provides novel solid state forms of Compound (I) selected from Form B, citric acid cocrystal Form A, piperazine cocrystal Form A, urea cocrystal Form A, nicotinamide cocrystal Form A, nicotinamide cocrystal Form B, aspartame cocrystal Form A, glutaric acid cocrystal Form A, L-proline cocrystal Form A, L-proline cocrystal Form B, vanillin cocrystal Form A, and 2-pyridone cocrystal Form A, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.
(FR) La présente divulgation concerne de nouvelles formes à l'état solide du composé (I) choisi parmi la forme B, la forme A du cocristal d'acide citrique, la pipérazine A, la forme A du cocristal d'urée, la forme A du cocristal de nicotinamide, la forme B du cocristal de nicotinamide, la forme A du cocristal de l'aspartame, la forme A du cocristal de l'acide glutarique, la forme A du cocristal de L-proline, la forme B du cocristal de L-proline, la forme A du cocristal de la vanilline, et la forme A du cocristal de 2-pyridone, des compositions les comprenant, et des procédés d'utilisation associés, comprenant l'utilisation dans le traitement d'une maladie rénale à médiation par APOL1.
Latest bibliographic data on file with the International Bureau